George Bakris to Treatment Outcome
This is a "connection" page, showing publications George Bakris has written about Treatment Outcome.
Connection Strength
4.048
-
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187.
Score: 0.084
-
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714.
Score: 0.079
-
Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254.
Score: 0.075
-
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
Score: 0.074
-
Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. Am J Kidney Dis. 2019 11; 74(5):573-575.
Score: 0.072
-
Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019 03 29; 124(7):969-971.
Score: 0.071
-
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 04; 20(4):694-702.
Score: 0.066
-
Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1309-1318.
Score: 0.064
-
MY APPROACH to the elderly patient with resistant hypertension. Trends Cardiovasc Med. 2018 01; 28(1):79-80.
Score: 0.064
-
Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846.
Score: 0.063
-
Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. J Clin Hypertens (Greenwich). 2017 Nov; 19(11):1202-1203.
Score: 0.063
-
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017 06; 19(6):792-799.
Score: 0.060
-
Current Status of Renal Denervation in Hypertension. Curr Cardiol Rep. 2016 11; 18(11):107.
Score: 0.060
-
The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015 Oct 17; 386(10003):1588-98.
Score: 0.056
-
New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension. 2015 Oct; 66(4):731-8.
Score: 0.055
-
Summary and Conclusions. High Blood Press Cardiovasc Prev. 2015 Jul; 22 Suppl 1:S23.
Score: 0.055
-
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321.
Score: 0.054
-
Renal denervation for resistant hypertension and beyond. Adv Chronic Kidney Dis. 2015 Mar; 22(2):133-9.
Score: 0.053
-
Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8.
Score: 0.053
-
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27.
Score: 0.052
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
Score: 0.051
-
Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6.
Score: 0.047
-
Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted? J Diabetes Complications. 2013 Sep-Oct; 27(5):415-6.
Score: 0.047
-
Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention. 2013 May; 9 Suppl R:R136-9.
Score: 0.047
-
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9.
Score: 0.047
-
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013 Mar; 9(3):147-53.
Score: 0.046
-
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100.
Score: 0.045
-
Approaches for targeting blood pressure control in sleep disorders. Curr Opin Nephrol Hypertens. 2012 Sep; 21(5):469-74.
Score: 0.045
-
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35.
Score: 0.044
-
Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr; 6(2):152-8.
Score: 0.043
-
Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage? Curr Opin Nephrol Hypertens. 2011 Sep; 20(5):471-5.
Score: 0.042
-
Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73.
Score: 0.041
-
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8.
Score: 0.040
-
Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83.
Score: 0.040
-
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30.
Score: 0.039
-
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):678-86.
Score: 0.039
-
Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31(5):469-70.
Score: 0.038
-
Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4.
Score: 0.037
-
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med. 2009 Mar; 121(2):77-88.
Score: 0.035
-
Newer combination therapies in the management of hypertension: an update. J Clin Hypertens (Greenwich). 2008 May; 10(5):398-405.
Score: 0.033
-
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
Score: 0.033
-
State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):130-9.
Score: 0.033
-
Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008 Feb; 10(2):146-52.
Score: 0.033
-
Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):112-8.
Score: 0.033
-
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
Score: 0.032
-
Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol. 2007 Sep; 27(5):555-64.
Score: 0.032
-
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Pol Arch Med Wewn. 2007 Sep; 117(9):389-90.
Score: 0.032
-
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007 Oct; 72(7):879-85.
Score: 0.032
-
Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. J Hum Hypertens. 2007 May; 21(5):347-52.
Score: 0.031
-
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9.
Score: 0.030
-
Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006 Oct 02; 98(7A):32L-38L.
Score: 0.030
-
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep. 2006 Jun; 6(3):219-24.
Score: 0.029
-
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens. 2006 Sep; 20(9):693-700.
Score: 0.029
-
Are beta blockers passé for the treatment of hypertension? J Clin Hypertens (Greenwich). 2006 Apr; 8(4):239-40.
Score: 0.029
-
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7.
Score: 0.028
-
Hypertension treatment guidelines: practical implications. Semin Nephrol. 2005 Jul; 25(4):198-209.
Score: 0.027
-
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005 Jun; 7(6):354-6.
Score: 0.027
-
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
Score: 0.027
-
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich). 2005 Feb; 7(2):73-80.
Score: 0.027
-
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004 Nov; 44(5):637-42.
Score: 0.026
-
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4.
Score: 0.026
-
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
Score: 0.025
-
The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004 Mar; 13(2):155-61.
Score: 0.025
-
What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207.
Score: 0.025
-
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003 May-Jun; 5(3):202-9.
Score: 0.023
-
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1.
Score: 0.023
-
Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12.
Score: 0.023
-
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 12 03; 400(10367):1927-1937.
Score: 0.023
-
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov; 20(11):2257-67.
Score: 0.023
-
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Fail. 2022 11; 10(11):860-870.
Score: 0.023
-
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416.
Score: 0.023
-
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31.
Score: 0.022
-
Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 02 14; 15(3):321-332.
Score: 0.022
-
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58.
Score: 0.021
-
Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47.
Score: 0.021
-
Choices and goals in the treatment of the diabetic hypertensive patient. Curr Hypertens Rep. 2001 Oct; 3(5):387-91.
Score: 0.021
-
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911.
Score: 0.021
-
Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 09; 98(3):416-426.
Score: 0.021
-
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539.
Score: 0.021
-
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638.
Score: 0.020
-
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001 Jan-Feb; 3(1):16-21.
Score: 0.020
-
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020 11; 8(11):903-914.
Score: 0.020
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229.
Score: 0.020
-
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
Score: 0.019
-
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452.
Score: 0.019
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356.
Score: 0.018
-
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 08 27; 140(9):739-750.
Score: 0.018
-
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
Score: 0.018
-
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550.
Score: 0.017
-
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail. 2018 08; 5(4):592-602.
Score: 0.017
-
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11).
Score: 0.017
-
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. J Am Coll Cardiol. 2018 03 27; 71(12):1379-1390.
Score: 0.016
-
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47.
Score: 0.016
-
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
Score: 0.016
-
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659.
Score: 0.016
-
High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84.
Score: 0.016
-
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701.
Score: 0.016
-
Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843.
Score: 0.015
-
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921.
Score: 0.015
-
An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017 02; 11(2):81-91.
Score: 0.015
-
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310.
Score: 0.015
-
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
Score: 0.015
-
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
Score: 0.014
-
Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9.
Score: 0.014
-
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015 Nov; 9(11):845-54.
Score: 0.014
-
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779.
Score: 0.014
-
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens Suppl. 1995 Aug; 13(2):S95-101.
Score: 0.014
-
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec; 20(12):953-8.
Score: 0.013
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
Score: 0.013
-
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43.
Score: 0.012
-
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):14-26.
Score: 0.012
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73.
Score: 0.012
-
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8.
Score: 0.012
-
Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8.
Score: 0.012
-
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol. 2013; 37(3):212-22.
Score: 0.012
-
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8.
Score: 0.011
-
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14.
Score: 0.011
-
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012 Nov; 33(22):2782-95.
Score: 0.011
-
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug; 60(2):310-8.
Score: 0.011
-
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012 May; 14(5):284-92.
Score: 0.011
-
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51.
Score: 0.011
-
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012 Apr; 125(4):399-410.
Score: 0.011
-
Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
Score: 0.011
-
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1.
Score: 0.010
-
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72.
Score: 0.010
-
Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol. 2011 May 01; 107(9):1338-45.
Score: 0.010
-
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20.
Score: 0.010
-
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9.
Score: 0.010
-
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Anesth Analg. 2010 Aug; 111(2):279-315.
Score: 0.010
-
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Catheter Cardiovasc Interv. 2010 Aug 01; 76(2):E43-86.
Score: 0.010
-
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 07; 304(1):61-8.
Score: 0.010
-
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010; 31(2):95-103.
Score: 0.009
-
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
Score: 0.009
-
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31.
Score: 0.009
-
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14; 118(16):1643-50.
Score: 0.009
-
Beta-blockers in the treatment of hypertension: new data, new directions. J Clin Hypertens (Greenwich). 2008 Mar; 10(3):234-8.
Score: 0.008
-
Beta-blocker therapy in hypertension: a need to pause and reflect. J Am Coll Cardiol. 2008 Jan 29; 51(4):516-7; author reply 517-8.
Score: 0.008
-
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36.
Score: 0.008
-
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17.
Score: 0.008
-
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
Score: 0.008
-
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007 Aug; 50(2):299-305.
Score: 0.008
-
beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007 May; 9(3):408-17.
Score: 0.008
-
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May; 9(5):355-64.
Score: 0.008
-
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007 Jul; 24(7):759-63.
Score: 0.008
-
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):840-9.
Score: 0.008
-
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3.
Score: 0.007
-
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
Score: 0.007
-
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
Score: 0.007
-
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005 Jun; 18(6):797-804.
Score: 0.007
-
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
Score: 0.006
-
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
Score: 0.006
-
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9.
Score: 0.006
-
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
Score: 0.006
-
Roundtable discussion: problems in the management of hypertension. J Clin Hypertens (Greenwich). 2002 May-Jun; 4(3):207-13.
Score: 0.005